Results 171 to 180 of about 18,044 (238)

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection. [PDF]

Allergy Asthma Immunol Res
Yun JE, Song WJ.
europepmc   +1 more source

Biosimilar [PDF]

, 2020
openaire   +1 more source

Law & Health Care Newsletter, Summer 2018 [PDF]

, 2018

core   +1 more source

Regulatory Requirements for Interchangeable Biosimilar Designation. [PDF]

Ther Innov Regul Sci
Samy PJ, Mouslim MC, Bennett CL, Trujillo AJ.   +3 more
europepmc   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. [PDF]

Front Pharmacol
Song Y, Shin G, Choi G, Han E, Ou HT, Bae S.   +5 more
europepmc   +1 more source